Amalgamated Bank Sells 1,136 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Amalgamated Bank lowered its position in Exelixis, Inc. (NASDAQ:EXELGet Rating) by 0.5% during the first quarter, according to its most recent filing with the SEC. The firm owned 232,559 shares of the biotechnology company’s stock after selling 1,136 shares during the period. Amalgamated Bank owned 0.07% of Exelixis worth $5,272,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC lifted its position in shares of Exelixis by 9.8% in the 1st quarter. CWM LLC now owns 5,137 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 460 shares during the period. Quadrant Capital Group LLC lifted its position in shares of Exelixis by 72.4% in the 1st quarter. Quadrant Capital Group LLC now owns 1,241 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 521 shares during the period. Arizona State Retirement System lifted its position in shares of Exelixis by 0.9% in the 1st quarter. Arizona State Retirement System now owns 85,527 shares of the biotechnology company’s stock worth $1,939,000 after purchasing an additional 733 shares during the period. Crossmark Global Holdings Inc. lifted its position in shares of Exelixis by 2.6% in the 1st quarter. Crossmark Global Holdings Inc. now owns 31,310 shares of the biotechnology company’s stock worth $709,000 after purchasing an additional 800 shares during the period. Finally, Covestor Ltd lifted its position in shares of Exelixis by 245.6% in the 1st quarter. Covestor Ltd now owns 1,676 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,191 shares during the period. Institutional investors and hedge funds own 85.25% of the company’s stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 40,000 shares of the business’s stock in a transaction on Monday, September 12th. The shares were sold at an average price of $17.94, for a total transaction of $717,600.00. Following the completion of the sale, the executive vice president now owns 261,591 shares in the company, valued at approximately $4,692,942.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.90% of the stock is currently owned by company insiders.

Exelixis Trading Down 1.3 %

Shares of EXEL stock opened at $16.92 on Tuesday. The firm has a market capitalization of $5.45 billion, a PE ratio of 20.14, a price-to-earnings-growth ratio of 0.54 and a beta of 0.65. The firm has a fifty day simple moving average of $19.58 and a two-hundred day simple moving average of $20.38. Exelixis, Inc. has a 12 month low of $15.50 and a 12 month high of $23.40.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of recent analyst reports. BMO Capital Markets began coverage on shares of Exelixis in a research report on Thursday, June 23rd. They issued an “outperform” rating and a $28.00 price target on the stock. Piper Sandler boosted their target price on shares of Exelixis from $30.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, July 26th. TheStreet downgraded shares of Exelixis from a “b-” rating to a “c+” rating in a research report on Tuesday, September 13th. Morgan Stanley boosted their target price on shares of Exelixis from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Friday, July 15th. Finally, Cowen boosted their target price on shares of Exelixis to $26.00 in a research report on Monday, August 15th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $30.56.

Exelixis Profile

(Get Rating)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Stories

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.